Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Mar 21, 2023 10:39pm
210 Views
Post# 35352789

RE:RE:EGF asset

RE:RE:EGF asset
fuzzyjr wrote: so what do you see as the best hope or move for Bti moving Prop?


Very tough time in the market. The S&P Biotech ETF is below where it was when the Midatech deal was announced. There has been a string of bank failures and there is concern the bank runs aren't over. An influencial JP Morgan analyst sees the growing risk of a Minsky Moment and total meltdown in the market. The market is more worried about the return of its money than speculation. And here BTI is caught without cash, significantly in debt, and needing significant money to material catalysts. Not a good position to be in.

BTI has a number of potential paths to create value at the current price as has been discussed. It may come down to the value a few people in a room put on a deal(s). That can be hard to estimate. There is considerable potential in BTI's assets. Rathjen aimed for the stars with the Midatech deal. She's got J&J and Chiesi around the table. It wil be interesting to see what happens.


<< Previous
Bullboard Posts
Next >>